Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06470295 · ClinicalTrials.gov registry record · Early Phase 1
Effect of C-peptide on Hypoglycemic Counterregulation
A Early Phase 1 study of Type 1 Diabetes and Hypoglycemia, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06470295 is a Early Phase 1 study of Type 1 Diabetes and Hypoglycemia that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 38 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06470295, a Early Phase 1 study of Type 1 Diabetes and Hypoglycemia, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.
Conditions Studied
Interventions
- OTHER Saline
- BIOLOGICAL C-peptide
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2028-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06470295
The ClinicalTrials.gov registry entry for NCT06470295 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06470295 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06470295 about?
NCT06470295 is a clinical study titled "Effect of C-peptide on Hypoglycemic Counterregulation". Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose ...
What is the current status of trial NCT06470295?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2024-06-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06470295 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Hypoglycemia.
What interventions are being tested in trial NCT06470295?
The interventions under investigation include: Saline (OTHER), C-peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT06470295?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06470295 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
RECRUITING · Early Phase 1
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
COMPLETED · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
-
Early Markers of Disease and Response to Therapy
COMPLETED · Early Phase 1
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.